SynAct Pharma
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här SynAct Participating at Redeye Autoimmune and Inflammatory Diseases event on November 19th
SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, announced that the company will present at Redeye’s Autoimmune and Inflammatory Diseases event in Stockholm on November 19th at 14:05 CET.
SynAct’s Chief Business Officer Mads Bjerregaard will present the latest on lead compound resomelagon, a potential first-in-class, non-suppressive immune system modulator, and the potential use in treatments for rheumatoid arthritis and acute inflammation due to viral infections.
“I’m excited to join peers from Swedish biotech at the Redeye event presenting our innovations in the field of immunology,” said Mads Bjerregaard, CSO at SynAct. “We believe that resomelagon is a novel approach to help patients overcome inflammatory disorder and we are excited to share our updates with investors in this important field of medicine.”
To view the presentation online use the following link:
https://www.redeye.se/events/1112314/redeye-theme-autoimmune-and-inflammatory-diseases-2
| Datum | 2025-11-19, kl 07:30 |
| Källa | MFN |